Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Dec;40(12):2760–2764. doi: 10.1128/aac.40.12.2760

High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

C Janoir 1, V Zeller 1, M D Kitzis 1, N J Moreau 1, L Gutmann 1
PMCID: PMC163617  PMID: 9124836

Abstract

The mechanism of high-level fluoroquinolone resistance was studied in strains of Streptococcus pneumoniae, either selected in vitro or isolated from clinical samples. By using DNA from these high-level-resistant strains, low-level-resistant transformants (MIC of pefloxacin, > or = 32 micrograms/ml; MIC of ciprofloxacin, 4 micrograms/ml; MIC of sparfloxacin, 0.50 micrograms/ml) were obtained at high frequencies (ca.10(-2)), while high-level-resistant transformants (MIC of pefloxacin, > or = 64 micrograms/ml; MIC of ciprofloxacin, 16 to 64 micrograms/ml; MIC of sparfloxacin, > or = 8 micrograms/ml) were obtained only at low frequencies (ca.10(-4)). This suggested that mutations in at least two unlinked genes were necessary to obtain high-level resistance. Low-level resistance was associated with ParC mutations (change from Ser to Tyr at position 79 [Ser79Tyr], Ser79Phe, or Asp83Gly). ParC mutations were associated, in high-level-resistant strains and transformants, with alterations in the quinolone resistance-determining region of GyrA (Ser84Tyr, Ser84Phe, and/or Glu88Lys). Low-level resistance was shown to be necessary for expression of the gyrA mutations. No mutation in the region corresponding to the quinolone resistance-determining region of GyrB and no alteration of drug accumulation were found.

Full Text

The Full Text of this article is available as a PDF (223.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  2. Belland R. J., Morrison S. G., Ison C., Huang W. M. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol. 1994 Oct;14(2):371–380. doi: 10.1111/j.1365-2958.1994.tb01297.x. [DOI] [PubMed] [Google Scholar]
  3. Bernard Louis, Nguyen Van Jean-Claude, Mainardi Jean-Luc. In Vivo Selection of Streptococcus pneumoniae, Resistant to Quinolones, Including Sparfloxin. Clin Microbiol Infect. 1995 Sep;1(1):60–61. doi: 10.1111/j.1469-0691.1995.tb00027.x. [DOI] [PubMed] [Google Scholar]
  4. Brockbank S. M., Barth P. T. Cloning, sequencing, and expression of the DNA gyrase genes from Staphylococcus aureus. J Bacteriol. 1993 Jun;175(11):3269–3277. doi: 10.1128/jb.175.11.3269-3277.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cambau E., Gutmann L. Mechanisms of resistance to quinolones. Drugs. 1993;45 (Suppl 3):15–23. doi: 10.2165/00003495-199300453-00005. [DOI] [PubMed] [Google Scholar]
  6. Cantón E., Pemán J., Jimenez M. T., Ramón M. S., Gobernado M. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob Agents Chemother. 1992 Mar;36(3):558–565. doi: 10.1128/aac.36.3.558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cooper M. A., Andrews J. M., Ashby J. P., Matthews R. S., Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1990 Nov;26(5):667–676. doi: 10.1093/jac/26.5.667. [DOI] [PubMed] [Google Scholar]
  8. Deguchi T., Yasuda M., Asano M., Tada K., Iwata H., Komeda H., Ezaki T., Saito I., Kawada Y. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1995 Feb;39(2):561–563. doi: 10.1128/aac.39.2.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Denis A., Moreau N. J. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition. J Antimicrob Chemother. 1993 Sep;32(3):379–392. doi: 10.1093/jac/32.3.379. [DOI] [PubMed] [Google Scholar]
  10. Fernandes C. J., Ackerman V. P. In vitro studies of ciprofloxacin and survey of resistance patterns in current isolates. Diagn Microbiol Infect Dis. 1990 Mar-Apr;13(2):79–91. doi: 10.1016/0732-8893(90)90090-i. [DOI] [PubMed] [Google Scholar]
  11. Ferrero L., Cameron B., Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother. 1995 Jul;39(7):1554–1558. doi: 10.1128/aac.39.7.1554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ferrero L., Cameron B., Manse B., Lagneaux D., Crouzet J., Famechon A., Blanche F. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol. 1994 Aug;13(4):641–653. doi: 10.1111/j.1365-2958.1994.tb00458.x. [DOI] [PubMed] [Google Scholar]
  13. Goswitz J. J., Willard K. E., Fasching C. E., Peterson L. R. Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob Agents Chemother. 1992 May;36(5):1166–1169. doi: 10.1128/aac.36.5.1166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother. 1996 Apr;40(4):879–885. doi: 10.1128/aac.40.4.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hooper D. C., Wolfson J. S., Souza K. S., Tung C., McHugh G. L., Swartz M. N. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother. 1986 Apr;29(4):639–644. doi: 10.1128/aac.29.4.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ito H., Yoshida H., Bogaki-Shonai M., Niga T., Hattori H., Nakamura S. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Sep;38(9):2014–2023. doi: 10.1128/aac.38.9.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kaatz G. W., Seo S. M., Ruble C. A. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J Infect Dis. 1991 May;163(5):1080–1086. doi: 10.1093/infdis/163.5.1080. [DOI] [PubMed] [Google Scholar]
  18. Khodursky A. B., Zechiedrich E. L., Cozzarelli N. R. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11801–11805. doi: 10.1073/pnas.92.25.11801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Korten V., Huang W. M., Murray B. E. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother. 1994 Sep;38(9):2091–2094. doi: 10.1128/aac.38.9.2091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. LACKS S., HOTCHKISS R. D. A study of the genetic material determining an enzyme in Pneumococcus. Biochim Biophys Acta. 1960 Apr 22;39:508–518. doi: 10.1016/0006-3002(60)90205-5. [DOI] [PubMed] [Google Scholar]
  21. Lafredo S. C., Foleno B. D., Fu K. P. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro. Chemotherapy. 1993;39(1):36–39. doi: 10.1159/000238971. [DOI] [PubMed] [Google Scholar]
  22. Laible G., Hakenbeck R., Sicard M. A., Joris B., Ghuysen J. M. Nucleotide sequences of the pbpX genes encoding the penicillin-binding proteins 2x from Streptococcus pneumoniae R6 and a cefotaxime-resistant mutant, C506. Mol Microbiol. 1989 Oct;3(10):1337–1348. doi: 10.1111/j.1365-2958.1989.tb00115.x. [DOI] [PubMed] [Google Scholar]
  23. Lefevre J. C., Claverys J. P., Sicard A. M. Donor deoxyribonucleic acid length and marker effect in pneumococcal transformation. J Bacteriol. 1979 Apr;138(1):80–86. doi: 10.1128/jb.138.1.80-86.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Margerrison E. E., Hopewell R., Fisher L. M. Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J Bacteriol. 1992 Mar;174(5):1596–1603. doi: 10.1128/jb.174.5.1596-1603.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Muñoz R., Bustamante M., de la Campa A. G. Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance. J Bacteriol. 1995 Jul;177(14):4166–4170. doi: 10.1128/jb.177.14.4166-4170.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. OTTOLENGHI E., HOTCHKISS R. D. Release of genetic transforming agent from pneumococcal cultures during growth and disintegration. J Exp Med. 1962 Oct 1;116:491–519. doi: 10.1084/jem.116.4.491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pan X. S., Fisher L. M. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol. 1996 Jul;178(14):4060–4069. doi: 10.1128/jb.178.14.4060-4069.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Piddock L. J., Wise R. The selection and frequency of streptococci with decreased susceptibility to ofloxacin compared with other quinolones. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):45–51. doi: 10.1093/jac/22.supplement_c.45. [DOI] [PubMed] [Google Scholar]
  29. Pérez-Trallero E., Garcia-Arenzana J. M., Jimenez J. A., Peris A. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1990 Dec;9(12):905–906. doi: 10.1007/BF01967510. [DOI] [PubMed] [Google Scholar]
  30. Sreedharan S., Peterson L. R., Fisher L. M. Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 1991 Oct;35(10):2151–2154. doi: 10.1128/aac.35.10.2151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Takenouchi T., Ishii C., Sugawara M., Tokue Y., Ohya S. Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob Agents Chemother. 1995 Jul;39(7):1414–1418. doi: 10.1128/aac.39.7.1414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Thomson K. S., Sanders C. C. Dissociated resistance among fluoroquinolones. Antimicrob Agents Chemother. 1994 Sep;38(9):2095–2100. doi: 10.1128/aac.38.9.2095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Thys J. P., Jacobs F., Byl B. Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):304–315. doi: 10.1007/BF01967004. [DOI] [PubMed] [Google Scholar]
  34. Tiraby J. G., Fox M. S. Marker discrimination in transformation and mutation of pneumococcus. Proc Natl Acad Sci U S A. 1973 Dec;70(12):3541–3545. doi: 10.1073/pnas.70.12.3541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Yamagishi J., Yoshida H., Yamayoshi M., Nakamura S. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet. 1986 Sep;204(3):367–373. doi: 10.1007/BF00331012. [DOI] [PubMed] [Google Scholar]
  36. Yoshida H., Bogaki M., Nakamura M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother. 1990 Jun;34(6):1271–1272. doi: 10.1128/aac.34.6.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yoshida H., Bogaki M., Nakamura M., Yamanaka L. M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother. 1991 Aug;35(8):1647–1650. doi: 10.1128/aac.35.8.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Yoshida H., Kojima T., Yamagishi J., Nakamura S. Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet. 1988 Jan;211(1):1–7. doi: 10.1007/BF00338386. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES